66 related articles for article (PubMed ID: 25960241)
41. Activation of AMPKα mediates additive effects of solamargine and metformin on suppressing MUC1 expression in castration-resistant prostate cancer cells.
Xiang S; Zhang Q; Tang Q; Zheng F; Wu J; Yang L; Hann SS
Sci Rep; 2016 Nov; 6():36721. PubMed ID: 27830724
[TBL] [Abstract][Full Text] [Related]
42. Effects of HIV protease, nucleoside/non-nucleoside reverse transcriptase inhibitors on Bax, Bcl-2 and apoptosis in two cervical cell lines.
Adefolaju GA; Theron KE; Hosie MJ
Biomed Pharmacother; 2014 Mar; 68(2):241-51. PubMed ID: 24011602
[TBL] [Abstract][Full Text] [Related]
43. MUC1 promotes cervical squamous cell carcinoma through ERK phosphorylation-mediated regulation of ITGA2/ITGA3.
Zhao A; Pan Y; Gao Y; Zhi Z; Lu H; Dong B; Zhang X; Wu M; Zhu F; Zhou S; Ma S
BMC Cancer; 2024 May; 24(1):559. PubMed ID: 38702644
[TBL] [Abstract][Full Text] [Related]
44. The effects of HAART on the expression of MUC1 and P65 in a cervical cancer cell line, HCS-2.
Thabethe KR; Adefolaju GA; Hosie MJ
Biomed Pharmacother; 2015 Apr; 71():227-32. PubMed ID: 25960241
[TBL] [Abstract][Full Text] [Related]
45. AIDS malignancies in the era of highly active antiretroviral therapy.
Gates AE; Kaplan LD
Oncology (Williston Park); 2002 May; 16(5):657-65; discussion 665, 668-70. PubMed ID: 12108891
[TBL] [Abstract][Full Text] [Related]
46. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
Pozio E
Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
[TBL] [Abstract][Full Text] [Related]
47. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
48. [AIDS associated cancers in the era of highly active antiretroviral therapy (HAART)].
Tserenpuntsag B; Kołacińska A; Jabłonowska E
Przegl Epidemiol; 2007; 61(3):529-34. PubMed ID: 18069390
[TBL] [Abstract][Full Text] [Related]
49. AIDS malignancies in the era of highly active antiretroviral therapy.
Gates AE; Kaplan LD
Oncology (Williston Park); 2002 Apr; 16(4):441-51, 456, 459. PubMed ID: 12017534
[TBL] [Abstract][Full Text] [Related]
50. [Epidemiology of HIV-associated malignancies].
Launay O; Guillevin L
Bull Cancer; 2003 May; 90(5):387-92. PubMed ID: 12850760
[TBL] [Abstract][Full Text] [Related]
51. Therapeutic approaches to AIDS-related malignancies.
Berretta M; Cinelli R; Martellotta F; Spina M; Vaccher E; Tirelli U
Oncogene; 2003 Sep; 22(42):6646-59. PubMed ID: 14528290
[TBL] [Abstract][Full Text] [Related]
52.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
53.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
